Related references
Note: Only part of the references are listed.Targeting PCSK9 in Liver Cancer Cells Triggers Metabolic Exhaustion and Cell Death by Ferroptosis
Malak Alannan et al.
CELLS (2023)
Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond
Thomas Grewal et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Caffeine blocks SREBP2-induced hepatic PCSK9 expression to enhance LDLR-mediated cholesterol clearance
Paul F. Lebeau et al.
NATURE COMMUNICATIONS (2022)
Gene Therapy Targeting PCSK9
Julius L. Katzmann et al.
METABOLITES (2022)
PCSK9 Promotes Cardiovascular Diseases: Recent Evidence about Its Association with Platelet Activation-Induced Myocardial Infarction
Meidi Utami Puteri et al.
LIFE-BASEL (2022)
Effect of PCSK9 Inhibitors on Hemostasis in Patients with Isolated Hypercholesterolemia
Marcin Basiak et al.
JOURNAL OF CLINICAL MEDICINE (2022)
PCSK9 Contributes to the Cholesterol, Glucose, and Insulin2 Homeostasis in Seminiferous Tubules and Maintenance of Immunotolerance in Testis
R. -Marc Pelletier et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2022)
Insight into the Evolving Role of PCSK9
Mateusz Maliglowka et al.
METABOLITES (2022)
PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis
Xing Wang et al.
CARDIOVASCULAR DIABETOLOGY (2022)
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond
Nabil G. Seidah et al.
CURRENT ATHEROSCLEROSIS REPORTS (2022)
Inclisiran: How Widely and When Should We Use It?
Angela Pirillo et al.
CURRENT ATHEROSCLEROSIS REPORTS (2022)
PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity
Malak Alannan et al.
CELLS (2022)
PCSK9 Affects Astrocyte Cholesterol Metabolism and Reduces Neuron Cholesterol Supplying In Vitro: Potential Implications in Alzheimer's Disease
Bianca Papotti et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
PCSK9 Inhibition: From Current Advances to Evolving Future
Chunping Liu et al.
CELLS (2022)
Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials
Wolfgang Koenig et al.
CARDIOVASCULAR DRUGS AND THERAPY (2022)
Association between the rs615563 variant of PCSK9 gene and circulating lipids and Type 2 diabetes
Samira Taghizadeh Jazdani et al.
BMC RESEARCH NOTES (2021)
A Systematic Approach to Assess the Activity and Classification of PCSK9 Variants
Kepa B. Uribe et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Mutational Spectrum of LDLR and PCSK9 Genes Identified in Iranian Patients With Premature Coronary Artery Disease and Familial Hypercholesterolemia
Arman Moradi et al.
FRONTIERS IN GENETICS (2021)
Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study
Stephen J. Nicholls et al.
CARDIOVASCULAR DIAGNOSIS AND THERAPY (2021)
Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications
Xiao-dan Xia et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)
PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
Aureli Luquero et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)
PCSK9 Biology and Its Role in Atherothrombosis
Cristina Barale et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology
Sai Sahana Sundararaman et al.
BIOMEDICINES (2021)
Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9
Charles A. German et al.
BIODRUGS (2020)
PCSK9 Inhibitors' New Users: Analysis of Prescription Patterns and Patients' Characteristics from an Italian Real-world Study
Carlo Piccinni et al.
CLINICAL DRUG INVESTIGATION (2020)
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
Jan Boren et al.
EUROPEAN HEART JOURNAL (2020)
An Update on the Role of PCSK9 in Atherosclerosis
Ece Yurtseven et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2020)
Clinical implications and outcomes of the ORION Phase III trials
Julia Brandts et al.
FUTURE CARDIOLOGY (2020)
PCSK9Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis
Qianyun Guo et al.
FRONTIERS IN GENETICS (2020)
Adaptive Immune Responses in Human Atherosclerosis
Silvia Lee et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Estimation of the major cardiovascular events prevention with Inclisiran
Alberto Cordero et al.
ATHEROSCLEROSIS (2020)
LDL, LDL receptors, and PCSK9 as modulators of the risk for type 2 diabetes: a focus on white adipose tissue
May Faraj
JOURNAL OF BIOMEDICAL RESEARCH (2020)
Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin tyoe-9 and is required for the degration of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9
Hyun-Duk Jang et al.
EUROPEAN HEART JOURNAL (2020)
Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update
Rasha Kaddoura et al.
JOURNAL OF DRUG ASSESSMENT (2020)
NLRP3 inflammasome via IL-1 13 regulates PCSK9 secretion
Zufeng Ding et al.
THERANOSTICS (2020)
Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis-Menten Approximation of a Target-Mediated Drug Disposition ModelSupport for a Biologics License Application Submission: Part I
Jean-Marie Martinez et al.
CLINICAL PHARMACOKINETICS (2019)
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Kausik K. Ray et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
被撤回的出版物: Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis (Retracted article. See vol. 21, 2023)
Amir Abbas Momtazi-Borojeni et al.
BMC MEDICINE (2019)
Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries
Toshiyuki Nishikido et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2019)
PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages
Zufeng Ding et al.
CARDIOVASCULAR RESEARCH (2018)
PCSK9 From Basic Science Discoveries to Clinical Trials
Michael D. Shapiro et al.
CIRCULATION RESEARCH (2018)
Mice Fed a High-Cholesterol Diet Supplemented with Quercetin-3-Glucoside Show Attenuated Hyperlipidemia and Hyperinsulinemia Associated with Differential Regulation of PCSK9 and LDLR in their Liver and Pancreas
Majambu Mbikay et al.
MOLECULAR NUTRITION & FOOD RESEARCH (2018)
PCSK9 induces a pro-inflammatory response in macrophages
Chiara Ricci et al.
SCIENTIFIC REPORTS (2018)
Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors
Dionne M. Hines et al.
VASCULAR HEALTH AND RISK MANAGEMENT (2018)
Monocyte-Macrophages and T Cells in Atherosclerosis
Ira Tabas et al.
IMMUNITY (2017)
Lipid Lowering Therapy and Circulating PCSK9 Concentration
Tsuyoshi Nozue
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2017)
Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation
Daniele Pastori et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
Robert P. Giugliano et al.
LANCET (2017)
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Regulation of PCSK9 by nutraceuticals
Amir Abbas Momtazi et al.
PHARMACOLOGICAL RESEARCH (2017)
PCSK9 signaling pathways and their potential importance in clinical practice
Michal Wicinski et al.
EPMA JOURNAL (2017)
Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies
Nassim Djebli et al.
CLINICAL PHARMACOKINETICS (2017)
New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway
Zhi-Han Tang et al.
ATHEROSCLEROSIS (2017)
Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease
Simon Glerup et al.
BASIC RESEARCH IN CARDIOLOGY (2017)
Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms
Hagai Tavori et al.
CARDIOVASCULAR RESEARCH (2016)
Unmet Needs in LDL-C Lowering: When Statins Won't Do!
Stephan Krahenbuhl et al.
DRUGS (2016)
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role
Frederick J. Raal et al.
JOURNAL OF LIPID RESEARCH (2016)
The Relationship between the Plasma PCSK9 Levels and Platelet Indices in Patients with Stable Coronary Artery Disease
Sha Li et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2015)
Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)
Daniel Gaudet et al.
AMERICAN JOURNAL OF CARDIOLOGY (2014)
Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor-Dependent and -Independent Mechanisms
Shirya Rashid et al.
CIRCULATION (2014)
PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells
Thomas A. Lagace
CURRENT OPINION IN LIPIDOLOGY (2014)
Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence
Arrigo F. G. Cicero et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2014)
Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts
My-Anh Nguyen et al.
JOURNAL OF LIPID RESEARCH (2014)
Delineation of molecular pathways that regulate hepatic PCSK9 and LDL receptor expression during fasting in normolipidemic hamsters
Minhao Wu et al.
ATHEROSCLEROSIS (2012)
Peroxisome Proliferator-activated Receptor γ Activation by Ligands and Dephosphorylation Induces Proprotein Convertase Subtilisin Kexin Type 9 and Low Density Lipoprotein Receptor Expression
Yajun Duan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
James M. McKenney et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
The Nuclear Factor NF-κB Pathway in Inflammation
Toby Lawrence
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2009)
Molecular basis for LDL receptor recognition by PCSK9
Hyock Joo Kwon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2
Steve Poirier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Share Paper
